Bladder transitional cell carcinoma – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Wed, 03 Jun 2026 04:05:44 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Bladder transitional cell carcinoma – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of TYRA-300-B01 tablets in patients with low grade, intermediate risk non-muscle invasive bladder cancer who have FGFR3 gene changes https://clinicaltrials.eu/trial/study-of-tyra-300-b01-tablets-in-patients-with-low-grade-intermediate-risk-non-muscle-invasive-bladder-cancer-who-have-fgfr3-gene-changes/ Wed, 27 May 2026 04:04:46 +0000 https://clinicaltrials.eu/trial/study-of-tyra-300-b01-tablets-in-patients-with-low-grade-intermediate-risk-non-muscle-invasive-bladder-cancer-who-have-fgfr3-gene-changes/ This study focuses on people with non-muscle invasive bladder cancer, specifically a type that has changes in a gene called FGFR3. The cancer in this study is classified as low grade and intermediate risk, which means it has certain characteristics such as returning within a year or appearing in multiple locations in the bladder. The study will test a new medication called TYRA-300, which comes in tablet form and is taken by mouth.

The purpose of this research is to evaluate how well TYRA-300 works and how safe it is for treating this specific type of bladder cancer. The study will last up to 24 months, during which participants will receive the study medication. Before starting the treatment, doctors will examine the bladder and identify specific areas of cancer to monitor throughout the study.

During the study, doctors will regularly check how the cancer responds to the treatment, particularly after the first 3 months. They will also monitor how long any positive responses to the treatment last and track any changes in the cancer over time. Throughout the study, participants will have regular check-ups to monitor their health and any effects of the medication.

]]> A study of loxo-435, enfortumab vedotin, and pembrolizumab in adults with advanced or metastatic bladder cancer https://clinicaltrials.eu/trial/a-study-of-loxo-435-enfortumab-vedotin-and-pembrolizumab-in-adults-with-advanced-or-metastatic-bladder-cancer/ Wed, 29 Apr 2026 15:10:00 +0000 https://clinicaltrials.eu/trial/a-study-of-loxo-435-enfortumab-vedotin-and-pembrolizumab-in-adults-with-advanced-or-metastatic-bladder-cancer/ This study focuses on individuals with Urothelial Carcinoma, a type of cancer that starts in the lining of the urinary tract, which may include Urinary Bladder Neoplasms. The research specifically targets cases that are locally advanced or have experienced Neoplasm Metastasis, meaning the cancer has spread to other parts of the body. The study is also focused on patients whose cancer has an FGFR3 genetic alteration, which is a specific change in the DNA of the cancer cells.

The purpose of this study is to test the effectiveness and safety of a new drug called vepugratinib compared to a placebo. Participants in the study will receive a combination of treatments. This includes vepugratinib or a placebo taken as an oral tablet, along with enfortumab vedotin and pembrolizumab, which are administered through intravenous use, meaning they are delivered directly into a vein. The study is designed so that neither the participants nor the researchers know which specific treatment is being administered during the process.

During the study, participants will undergo regular medical monitoring to track the progress of the treatment. The involvement in this clinical trial may last for up to approximately 6 years.

]]> Study of MK-3120 for patients with high-risk non-muscle invasive bladder cancer who have not received or have received BCG treatment https://clinicaltrials.eu/trial/study-of-mk-3120-for-patients-with-high-risk-non-muscle-invasive-bladder-cancer-who-have-not-received-or-have-received-bcg-treatment/ Wed, 29 Apr 2026 15:08:19 +0000 https://clinicaltrials.eu/trial/study-of-mk-3120-for-patients-with-high-risk-non-muscle-invasive-bladder-cancer-who-have-not-received-or-have-received-bcg-treatment/ This study is looking at a treatment for high-risk non-muscle invasive bladder cancer with a specific type called carcinoma in situ, which may occur with or without growths called papillary tumors. Non-muscle invasive bladder cancer means the cancer is present in the bladder lining but has not grown into the deeper muscle layer of the bladder wall. Carcinoma in situ is a flat form of cancer that stays in the inner layer of the bladder. The treatment being tested is called MK-3120, which is given directly into the bladder through a procedure called intravesical administration, meaning the medicine is placed inside the bladder rather than taken by mouth or injection into the bloodstream. The medicine is in the form of a suspension, which is a liquid mixture.

The purpose of this study is to evaluate the safety and tolerability of MK-3120 when used alone as a treatment. The study will look at how well people can handle the treatment and what side effects might occur. The study is divided into phases, with the first phase focusing on finding the right dose and understanding safety, while the second phase will look more closely at how well the treatment works. People taking part in this study will either have never received a treatment called BCG (Bacillus Calmette-Guérin), which is a common bladder cancer treatment, or they will have received BCG in the past but their cancer has returned. The study will track whether participants experience dose-limiting toxicity, which means side effects serious enough to require stopping or reducing the treatment dose, and will count how many people have adverse events or need to stop treatment because of side effects.

During the study, participants will receive MK-3120 directly into their bladder at scheduled times. The study will also measure the complete response rate, which means how many people have their cancer completely disappear after treatment. Before joining the study, participants must have had a procedure called transurethral resection of bladder tumor, which is a surgery to remove bladder tumors through the urethra, performed within a certain timeframe. The study will continue for several years to follow participants and gather information about the long-term effects of the treatment.

]]> A study comparing erdafitinib delivery system to chemotherapy for patients with high-risk non-muscle-invasive bladder cancer who received BCG treatment https://clinicaltrials.eu/trial/a-study-comparing-erdafitinib-delivery-system-to-chemotherapy-for-patients-with-high-risk-non-muscle-invasive-bladder-cancer-who-received-bcg-treatment/ Wed, 29 Apr 2026 15:07:47 +0000 https://clinicaltrials.eu/trial/a-study-comparing-erdafitinib-delivery-system-to-chemotherapy-for-patients-with-high-risk-non-muscle-invasive-bladder-cancer-who-received-bcg-treatment/ This study involves people with high-risk non-muscle-invasive bladder cancer who have specific changes in their genes called FGFR alterations. Non-muscle-invasive bladder cancer means the cancer is in the inner lining of the bladder but has not grown into the deeper muscle layer of the bladder wall. High-risk means the cancer is more likely to come back or get worse. These individuals have already received treatment with Bacillus Calmette-Guérin, which is a type of vaccine used to treat bladder cancer by placing it directly into the bladder, but the cancer has either come back or the treatment could not be completed due to side effects. The study will compare a new treatment method using erdafitinib delivered through a device placed inside the bladder called an intravesical delivery system, known as TAR-210, with standard chemotherapy treatments that are also placed directly into the bladder.

The chemotherapy options that doctors may choose from include gemcitabine or mitomycin, which are medications that work to kill cancer cells. The erdafitinib treatment is given using a special catheter device that places the medication directly into the bladder where it can stay and work over time. The purpose of this study is to find out if the erdafitinib delivery system works better than the standard chemotherapy treatments in preventing the cancer from coming back or getting worse.

People in the study will be randomly assigned to receive either the erdafitinib intravesical delivery system or one of the chemotherapy treatments chosen by their doctor. The study will follow participants over time to see how well each treatment works and to check for any side effects. Before joining the study, all visible tumors must be completely removed, and participants must have testing to confirm they have the specific FGFR changes that the erdafitinib treatment targets. The study is designed for people who cannot have or do not want surgery to remove their bladder.

]]> Study of nadofaragene firadenovec alone or with gemcitabine, docetaxel or pembrolizumab in adults with non-muscle invasive bladder cancer who did not respond to BCG therapy https://clinicaltrials.eu/trial/study-of-nadofaragene-firadenovec-alone-or-with-gemcitabine-docetaxel-or-pembrolizumab-in-adults-with-non-muscle-invasive-bladder-cancer-who-did-not-respond-to-bcg-therapy/ Wed, 29 Apr 2026 15:07:22 +0000 https://clinicaltrials.eu/trial/study-of-nadofaragene-firadenovec-alone-or-with-gemcitabine-docetaxel-or-pembrolizumab-in-adults-with-non-muscle-invasive-bladder-cancer-who-did-not-respond-to-bcg-therapy/ This study focuses on patients with non-muscle invasive bladder cancer who have not responded to previous treatment with Bacillus Calmette-Guerin therapy. The study will evaluate a new treatment approach using nadofaragene firadenovec, either alone or in combination with other medications. The combinations will include chemotherapy drugs (gemcitabine and docetaxel) or immunotherapy (pembrolizumab).

The purpose of this research is to determine how safe and effective these treatment combinations are for patients whose bladder cancer has not responded to standard therapy. The treatment involves placing medication directly into the bladder through a process called intravesical instillation. The study will monitor how well the cancer responds to these treatments over time.

During the study, which may last up to 24 months, participants will receive their assigned treatment according to a specific schedule. Some patients will receive only nadofaragene firadenovec, while others will receive it in combination with either chemotherapy or immunotherapy. The study will track whether the cancer disappears completely after treatment, which is called a complete response.

]]> Study of N-803 combined with BCG treatment for patients with early-stage bladder cancer that has not invaded the muscle wall https://clinicaltrials.eu/trial/study-of-n-803-combined-with-bcg-treatment-for-patients-with-early-stage-bladder-cancer-that-has-not-invaded-the-muscle-wall/ Wed, 29 Apr 2026 15:06:52 +0000 https://clinicaltrials.eu/trial/study-of-n-803-combined-with-bcg-treatment-for-patients-with-early-stage-bladder-cancer-that-has-not-invaded-the-muscle-wall/ This study focuses on patients with Non-Muscle Invasive Bladder Cancer, an early-stage cancer that affects the inner lining of the bladder without spreading to the muscle layer. The research evaluates a combination treatment using two medications: N-803 (also known as nogapendekin alfa inbakicept) and BCG (Bacillus Calmette-Guérin). BCG is an established treatment that helps stimulate the immune system to fight bladder cancer cells, while N-803 is a new medication being tested to enhance the effectiveness of BCG treatment.

The purpose of this research is to determine if combining N-803 with BCG works better than using BCG alone for treating early-stage bladder cancer. The study includes two groups of patients: those with a type of bladder cancer called carcinoma in situ (CIS) and those with high-grade papillary disease. Both medications are given directly into the bladder through a process called intravesical administration.

The treatment period lasts for 37 months, during which patients receive either the combination of N-803 and BCG or BCG alone. Throughout the study, doctors monitor the patients’ response to treatment using various examination methods to check if the cancer has responded to therapy or if it has returned. Regular check-ups include examining the bladder and collecting urine samples to test for cancer cells.

]]> Study on the Effectiveness of Durvalumab and BCG in Treating High-Risk, Non-Muscle Invasive Bladder Cancer in Patients New to BCG Treatment https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-durvalumab-and-bcg-in-treating-high-risk-non-muscle-invasive-bladder-cancer-in-patients-new-to-bcg-treatment/ Wed, 29 Apr 2026 15:05:36 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-durvalumab-and-bcg-in-treating-high-risk-non-muscle-invasive-bladder-cancer-in-patients-new-to-bcg-treatment/ This clinical trial is focused on studying the treatment of non-muscle invasive bladder cancer, a type of bladder cancer that has not spread into the muscle layer of the bladder. The study will evaluate the effectiveness and safety of a combination therapy using Durvalumab and Bacillus Calmette-Guérin (BCG), compared to the standard treatment of BCG alone. Durvalumab is a medication that helps the immune system fight cancer, while BCG is a vaccine that is used to treat bladder cancer by stimulating the immune system.

The purpose of the study is to assess how well the combination of Durvalumab and BCG works in preventing the return of cancer, known as disease-free survival. Participants in the study will receive either the combination therapy or BCG alone. The study will last for up to 12 months, during which participants will be monitored regularly to evaluate the treatment’s effectiveness and any side effects. The study aims to provide more information on whether adding Durvalumab to the standard BCG treatment can improve outcomes for patients with this type of bladder cancer.

Throughout the study, participants will undergo regular check-ups and assessments to track their health and the progress of the treatment. The study will also look at other important outcomes, such as the time it takes for the cancer to become muscle-invasive or spread, and the overall survival rate of participants. The information gathered from this study will help determine if the combination of Durvalumab and BCG is a more effective treatment option for patients with non-muscle invasive bladder cancer.

]]> Study of Nadofaragene Firadenovec for Adults with Intermediate Risk Non-Muscle Invasive Bladder Cancer https://clinicaltrials.eu/trial/study-of-nadofaragene-firadenovec-for-adults-with-intermediate-risk-non-muscle-invasive-bladder-cancer/ Wed, 29 Apr 2026 15:04:13 +0000 https://clinicaltrials.eu/trial/study-of-nadofaragene-firadenovec-for-adults-with-intermediate-risk-non-muscle-invasive-bladder-cancer/ This clinical trial is focused on studying a type of bladder cancer known as non-muscle invasive bladder cancer (NMIBC), specifically in patients who have an intermediate risk of the cancer returning or worsening. The treatment being tested is called nadofaragene firadenovec, also known by its code name ADSTILADRIN. This treatment is given as an intravesical suspension, which means it is administered directly into the bladder. The study aims to compare the effectiveness of this treatment with the standard practice of simply observing the patients without additional treatment.

The purpose of the study is to see if nadofaragene firadenovec can help prevent the cancer from coming back or getting worse. Participants in the study will receive the treatment every three months. The study will last for up to 24 months, during which time the health of the participants will be closely monitored. The main focus is on how long patients remain free from cancer recurrence, progression, or any cause of death during the study period.

Participants in the study will have already undergone a procedure called transurethral resection of the bladder tumor (TURBT), which is a common method for removing bladder tumors. The study will help determine if adding nadofaragene firadenovec to the treatment plan can improve outcomes for patients with intermediate risk NMIBC. The results of this study could provide valuable information on the potential benefits of this new treatment option for bladder cancer patients.

]]> Study on Avelumab for Patients with Advanced Urothelial Cancer After Initial Chemotherapy https://clinicaltrials.eu/trial/study-on-avelumab-for-patients-with-advanced-urothelial-cancer-after-initial-chemotherapy/ Wed, 29 Apr 2026 15:03:48 +0000 https://clinicaltrials.eu/trial/study-on-avelumab-for-patients-with-advanced-urothelial-cancer-after-initial-chemotherapy/ This clinical trial is focused on studying the effects of a treatment for urothelial cancer, which includes bladder cancer and muscle invasive bladder cancer. The treatment being tested is a medication called Bavencio, which contains the active substance avelumab. Avelumab is a type of protein that helps the immune system fight cancer cells. The medication is given as a solution through an intravenous infusion, meaning it is administered directly into the bloodstream through a vein.

The purpose of this study is to see if using avelumab for a short period, up to six months, can help patients with advanced urothelial cancer live longer. These patients have already received chemotherapy that includes platinum-based drugs, and their cancer has not worsened during or after this initial treatment. The study will observe patients over a period of 18 months to determine if the treatment improves their overall survival.

Participants in the study will receive either the avelumab treatment or a placebo. The study will monitor the patients’ health and response to the treatment over time, focusing on how long they live and how their cancer responds to the treatment. The trial aims to provide valuable information on whether avelumab can be an effective maintenance therapy for patients with this type of cancer.

]]> Study on the Safety and Effectiveness of Alpha1H for Adults with Non-Muscle Invasive Bladder Cancer Awaiting Tumor Removal Surgery https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-alpha1h-for-adults-with-non-muscle-invasive-bladder-cancer-awaiting-tumor-removal-surgery/ Wed, 29 Apr 2026 15:03:16 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-alpha1h-for-adults-with-non-muscle-invasive-bladder-cancer-awaiting-tumor-removal-surgery/ This clinical trial is focused on studying non-muscle invasive bladder cancer, a type of bladder cancer that has not spread into the muscle layer of the bladder. The study will evaluate a treatment called Alpha1H, which is a solution used for instillation directly into the bladder. The purpose of the study is to assess the safety and effectiveness of Alpha1H in patients who are waiting for surgery to remove their bladder tumor.

Participants in the study will receive either the Alpha1H treatment or a placebo. The treatment involves placing the solution into the bladder through a process called intravesical instillation, which means the solution is delivered directly into the bladder. The study will monitor how the treatment affects the cancer, including any changes in the size and shape of the tumor, and whether it causes cancer cells to shed into the urine. The study will also look at how the treatment affects the body overall, including any side effects that may occur.

The trial will include various assessments to understand the impact of Alpha1H on the cancer and the body. These assessments will involve examining the tumor tissue and urine samples to see how the treatment works at a cellular level. The study aims to provide valuable information about the potential benefits and safety of using Alpha1H for treating non-muscle invasive bladder cancer.

]]> Study of Eciskafusp Alfa and BCG for Patients with High-Risk Bladder Cancer Not Responding to BCG Treatment https://clinicaltrials.eu/trial/study-of-eciskafusp-alfa-and-bcg-for-patients-with-high-risk-bladder-cancer-not-responding-to-bcg-treatment/ Wed, 29 Apr 2026 15:03:12 +0000 https://clinicaltrials.eu/trial/study-of-eciskafusp-alfa-and-bcg-for-patients-with-high-risk-bladder-cancer-not-responding-to-bcg-treatment/ This clinical trial is focused on studying a type of bladder cancer known as high-risk non-muscle invasive bladder cancer that does not respond to a common treatment called Bacillus Calmette-Guérin (BCG). The study will explore a new treatment combination involving a medication called eciskafusp alfa and BCG. Eciskafusp alfa is being tested to see if it can help patients whose cancer has not been controlled by BCG alone.

The purpose of the study is to evaluate the safety and effectiveness of this new treatment combination. Participants will receive the treatment directly into the bladder, a method known as intravesical use. The study will be conducted in two phases. The first phase will focus on determining the safest dose of eciskafusp alfa when used with BCG. The second phase will assess how well the treatment works in preventing the cancer from returning or getting worse.

Throughout the study, participants will be monitored for any side effects and the overall response of their cancer to the treatment. The study aims to find out if this new combination can provide a better outcome for patients with this type of bladder cancer. Participants will undergo regular check-ups, including procedures like cystoscopy, which is a way to look inside the bladder, and imaging tests to track the progress of the treatment.

]]> Study on the Effectiveness and Safety of Mitomycin C with Electric Current for Treating Non-Muscle Invasive Bladder Cancer in Patients, Compared to Standard Immunotherapy https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-mitomycin-c-with-electric-current-for-treating-non-muscle-invasive-bladder-cancer-in-patients-compared-to-standard-immunotherapy/ Wed, 29 Apr 2026 15:02:49 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-mitomycin-c-with-electric-current-for-treating-non-muscle-invasive-bladder-cancer-in-patients-compared-to-standard-immunotherapy/ This clinical trial is focused on studying the treatment of non-muscle invasive bladder cancer (NMIBC), a type of bladder cancer that has not spread into the muscle layer of the bladder. The study is comparing two treatments: a supportive treatment using mitomycin C administered with the help of an electric current, known as EMDA-MMC, and the standard treatment using BCG immunotherapy. The purpose of the study is to evaluate how effective and safe these treatments are in managing NMIBC.

Participants in the study will receive either the EMDA-MMC treatment or the standard BCG treatment. Both treatments involve an initial phase of six weekly sessions, followed by a maintenance phase lasting one year. The study also aims to assess the effectiveness of a urinary biomarker called MCM5 ADXBLADDER in detecting the recurrence of tumors. This biomarker will be compared to traditional methods like urinary cytology and cystoscopy, which are procedures used to examine the bladder and detect cancer cells.

The trial will monitor participants over time to see how well the treatments work in preventing the return of cancer and to check for any side effects. The study will also look at how these treatments impact the quality of life of the participants. The findings from this study could help improve the management of high-grade NMIBC and provide insights into more effective ways to detect tumor recurrence.

]]> Study on Mitomycin and BCG for Patients with Recurrent Non-Muscle Invasive Bladder Cancer https://clinicaltrials.eu/trial/study-on-mitomycin-and-bcg-for-patients-with-recurrent-non-muscle-invasive-bladder-cancer/ Wed, 29 Apr 2026 15:02:02 +0000 https://clinicaltrials.eu/trial/study-on-mitomycin-and-bcg-for-patients-with-recurrent-non-muscle-invasive-bladder-cancer/ This clinical trial is focused on studying a type of bladder cancer known as recurrent non-muscle invasive bladder cancer. This form of cancer affects the bladder but does not invade the muscle layer. The study will explore two treatment options. The first treatment involves a medication called Mitomycin, which is used in a process called chemoablation. Chemoablation is a method where the medication is directly applied to the bladder to destroy cancer cells. The second treatment option is a standard procedure called transurethral resection of bladder tumor (TURBT), followed by additional therapy using another medication called BCG (Bacillus Calmette-Guérin), which is a type of bacteria used to stimulate the immune system to fight cancer cells.

The purpose of this study is to determine if the chemoablation treatment with Mitomycin is more effective in the long term compared to the standard TURBT procedure with BCG therapy. Participants in the study will be randomly assigned to receive either the Mitomycin treatment or the TURBT procedure with BCG. The study will monitor the participants over a period of time to see how well each treatment works in preventing the cancer from coming back.

Throughout the study, participants will receive regular check-ups to monitor their health and the effectiveness of the treatment. The study aims to provide valuable information on which treatment option offers better outcomes for patients with recurrent non-muscle invasive bladder cancer. This research could help improve future treatment strategies for this type of cancer.

]]> Study Comparing Gemcitabine and Mitomycin for Patients with Intermediate Risk Non-Muscle Invasive Bladder Cancer https://clinicaltrials.eu/trial/study-comparing-gemcitabine-and-mitomycin-for-patients-with-intermediate-risk-non-muscle-invasive-bladder-cancer/ Wed, 29 Apr 2026 15:00:01 +0000 https://clinicaltrials.eu/trial/study-comparing-gemcitabine-and-mitomycin-for-patients-with-intermediate-risk-non-muscle-invasive-bladder-cancer/ This clinical trial is focused on studying a type of bladder cancer known as non-muscle invasive bladder cancer (NMIBC), which has an intermediate risk of coming back after surgery. The study is comparing two treatments: Gemcitabine and Mitomycin. Gemcitabine is given as a solution for infusion, which means it is administered directly into the bladder, while Mitomycin is also given directly into the bladder as an intravesical solution. The purpose of the study is to see if Gemcitabine can help prevent the cancer from returning better than Mitomycin.

Participants in the study will receive one of the two treatments after their initial surgery to remove the bladder tumor. The study will last for a period of up to six months, during which the effects of the treatments will be monitored. The main focus is on how long patients remain free from cancer recurrence. Additionally, the study will look at other factors such as any side effects experienced, the overall health and quality of life of the participants, and the economic impact of the treatments.

This trial aims to provide valuable information on the effectiveness of these treatments in preventing the return of bladder cancer, potentially leading to improved treatment options for patients with intermediate-risk NMIBC. The study will help determine which treatment offers better outcomes in terms of keeping the cancer from coming back and maintaining the quality of life for patients.

]]> Study of Durvalumab and Tremelimumab for Patients with Advanced Unresectable Urothelial Cancer https://clinicaltrials.eu/trial/study-of-durvalumab-and-tremelimumab-for-patients-with-advanced-unresectable-urothelial-cancer/ Wed, 29 Apr 2026 14:58:31 +0000 https://clinicaltrials.eu/trial/study-of-durvalumab-and-tremelimumab-for-patients-with-advanced-unresectable-urothelial-cancer/ This clinical trial is focused on studying treatments for Stage IV Urothelial Cancer, a type of cancer that affects the urinary system, including the bladder, ureters, and urethra. The study involves patients whose cancer cannot be removed by surgery and who have not yet received chemotherapy. The trial will test the effectiveness of a medication called MEDI4736, also known as durvalumab, both on its own and in combination with another medication called tremelimumab. These treatments will be compared to the standard chemotherapy treatments currently used for this type of cancer.

The purpose of the study is to determine how well these new treatments work in extending the life of patients with this advanced cancer. Participants in the study will receive either the new treatment or the standard chemotherapy. Some participants may receive a combination of MEDI4736 and tremelimumab, while others will receive MEDI4736 alone. The study will also include a group of patients who will receive a placebo, which is a substance with no active medication, to compare the effects of the treatments.

Throughout the study, participants will receive regular check-ups and monitoring to assess their health and the progress of their cancer. The study aims to provide valuable information on whether these new treatments can offer better outcomes for patients with Stage IV Urothelial Cancer compared to the current standard of care. The trial is expected to continue until the end of 2025, with recruitment starting in September 2024.

]]> Study on Atezolizumab for Patients with High-Risk Muscle-Invasive Bladder Cancer with Positive ctDNA After Surgery https://clinicaltrials.eu/trial/study-on-atezolizumab-for-patients-with-high-risk-muscle-invasive-bladder-cancer-with-positive-ctdna-after-surgery/ Wed, 29 Apr 2026 14:57:14 +0000 https://clinicaltrials.eu/trial/study-on-atezolizumab-for-patients-with-high-risk-muscle-invasive-bladder-cancer-with-positive-ctdna-after-surgery/ This clinical trial is focused on studying high-risk muscle-invasive bladder cancer, a type of cancer that affects the bladder and can spread to other parts of the body. The study is investigating the effects of a treatment called atezolizumab, which is a type of medication known as an anti-PD-L1 antibody. This medication is designed to help the immune system recognize and fight cancer cells more effectively. The trial will compare the effects of atezolizumab with a placebo in patients who have undergone surgery to remove the bladder cancer and are found to have circulating tumor DNA (ctDNA) in their blood, which indicates a higher risk of cancer returning.

The purpose of the study is to evaluate how well atezolizumab works in preventing the return of cancer in these patients. Participants in the study will receive either atezolizumab or a placebo through an intravenous infusion, which means the medication is given directly into a vein. The study will monitor patients over a period of time to assess their disease-free survival, which refers to the length of time patients remain free from cancer after treatment. The study will also look at other factors, such as overall survival and the presence of any side effects from the treatment.

Throughout the study, patients will have regular check-ups and tests to monitor their health and the status of their cancer. These tests may include blood tests to check for ctDNA and other markers, as well as imaging tests to look for any signs of cancer returning. The study aims to provide valuable information on the effectiveness of atezolizumab as an additional therapy for patients with high-risk muscle-invasive bladder cancer, potentially offering a new option for preventing cancer recurrence in this group of patients.

]]> Study on Hexaminolevulinate for Patients with Non-Muscle Invasive Bladder Cancer to Reduce Need for Second Surgery https://clinicaltrials.eu/trial/study-on-hexaminolevulinate-for-patients-with-non-muscle-invasive-bladder-cancer-to-reduce-need-for-second-surgery/ Wed, 29 Apr 2026 14:56:53 +0000 https://clinicaltrials.eu/trial/study-on-hexaminolevulinate-for-patients-with-non-muscle-invasive-bladder-cancer-to-reduce-need-for-second-surgery/ This clinical trial is focused on studying non-muscle invasive bladder cancer (NMIBC), a type of bladder cancer that has not spread into the muscle layer of the bladder. The study is comparing two different surgical methods for removing bladder tumors. One method uses a special technique called Photodynamic Trans-urethral Resection of Bladder Tumors (PDD-TURBT), which involves using a light-sensitive drug called Hexvix (hexaminolevulinate) to help doctors see and remove the cancer more clearly. The other method is the conventional approach using white light during surgery, followed by a second surgery if needed.

The purpose of the study is to see if the PDD-TURBT method can help avoid the need for a second surgery without increasing the risk of cancer coming back. Participants in the study will be randomly assigned to one of the two surgical methods. After the surgery, they will be monitored for any signs of cancer returning, with follow-up checks scheduled over several months. The study aims to provide evidence on whether the new method can be as effective as the standard approach while potentially reducing the need for additional surgeries.

Throughout the study, researchers will compare the outcomes of patients who undergo the PDD-TURBT method with those who have the conventional surgery. They will look at how often the cancer returns, the time it takes for any recurrence, and the overall health and quality of life of the participants. The study will also assess the costs associated with each method to determine if the new approach could be more cost-effective in the long run. The findings from this study could help improve treatment guidelines for patients with NMIBC.

]]> Study of Cabozantinib and Durvalumab for Patients with Advanced Bladder Cancer After Chemotherapy https://clinicaltrials.eu/trial/study-of-cabozantinib-and-durvalumab-for-patients-with-advanced-bladder-cancer-after-chemotherapy/ Wed, 29 Apr 2026 14:56:46 +0000 https://clinicaltrials.eu/trial/study-of-cabozantinib-and-durvalumab-for-patients-with-advanced-bladder-cancer-after-chemotherapy/ This clinical trial is focused on studying the effects of a combination treatment for patients with advanced bladder cancer, specifically those who have already undergone chemotherapy. The diseases being studied include both urothelial and non-urothelial types of bladder cancer. The treatment involves two medications: Cabozantinib, which is taken as a tablet, and Durvalumab (also known as MEDI4736), which is given as an infusion. The purpose of the study is to see if using these two drugs together is more effective than using them separately.

Participants in the study will receive both Cabozantinib and Durvalumab. The study will monitor how well the combination works in treating the cancer and will also look at the overall survival of the patients. The trial will take place over a period of time, during which patients will be regularly assessed to track their response to the treatment. Some patients may receive a placebo as part of the study to compare the effects of the actual treatment.

The study aims to provide valuable information on whether this combination treatment can improve outcomes for patients with advanced bladder cancer. By participating, patients will contribute to research that could lead to better treatment options in the future. The trial is designed to ensure the safety and well-being of all participants, with regular check-ups and monitoring throughout the study period.

]]> Study on TAR-200 and Cetrelimab for Patients with High-Risk Non-Muscle Invasive Bladder Cancer Who Have Not Received BCG Treatment https://clinicaltrials.eu/trial/study-on-tar-200-and-cetrelimab-for-patients-with-high-risk-non-muscle-invasive-bladder-cancer-who-have-not-received-bcg-treatment/ Wed, 29 Apr 2026 14:30:27 +0000 https://clinicaltrials.eu/trial/study-on-tar-200-and-cetrelimab-for-patients-with-high-risk-non-muscle-invasive-bladder-cancer-who-have-not-received-bcg-treatment/ This clinical trial is focused on studying a type of bladder cancer known as High-Risk Non-Muscle Invasive Bladder Cancer (HRNMIBC). The study is evaluating the effectiveness and safety of a treatment called TAR-200, both on its own and in combination with another treatment called Cetrelimab, compared to a standard treatment known as Bacillus Calmette-Guérin (BCG). TAR-200 is a device that delivers medication directly to the bladder, while Cetrelimab is a type of medication known as a monoclonal antibody, which is a protein designed to help the immune system fight cancer.

The purpose of the study is to compare how well these treatments work in preventing the return or worsening of the cancer. Participants in the study will be divided into groups to receive either TAR-200 with Cetrelimab, TAR-200 alone, or the standard BCG treatment. The study will monitor participants over time to see how long they remain free from cancer recurrence or progression.

Throughout the study, participants will undergo various procedures, including regular check-ups and tests to assess their health and the status of their cancer. The study aims to provide valuable information on the potential benefits of these new treatment options for people with High-Risk Non-Muscle Invasive Bladder Cancer.

]]> Study on Bladder Cancer: Testing Cisplatin and Drug Combination for Patients with Non-Muscle Invasive Bladder Cancer https://clinicaltrials.eu/trial/study-on-bladder-cancer-testing-cisplatin-and-drug-combination-for-patients-with-non-muscle-invasive-bladder-cancer/ Wed, 29 Apr 2026 14:30:00 +0000 https://clinicaltrials.eu/trial/study-on-bladder-cancer-testing-cisplatin-and-drug-combination-for-patients-with-non-muscle-invasive-bladder-cancer/ This clinical trial is focused on studying a type of bladder cancer known as non-muscle invasive bladder cancer. The study aims to evaluate the effectiveness of a treatment approach that involves administering chemotherapy directly into the bladder before a surgical procedure called transurethral resection of the bladder (TURBT). This approach is being tested to see if it can help prevent the cancer from coming back.

The trial involves several chemotherapy medications, including cisplatin, doxorubicin hydrochloride, mitomycin, gemcitabine, docetaxel, and epirubicin hydrochloride. These medications are known as chemotherapeutic agents, which are drugs used to kill or stop the growth of cancer cells. In this study, these drugs are given directly into the bladder, a method known as intravesical use, to see if they can reduce the chances of the cancer returning after surgery.

The purpose of the study is to compare the rate of early cancer recurrence between patients who receive this chemotherapy treatment before surgery and those who undergo the surgery without the chemotherapy. Participants in the study will be randomly assigned to one of these two groups. The study will also monitor any side effects of the drugs used. The trial is expected to continue for several years to gather enough information to determine the effectiveness of this treatment approach.

]]> Study on TAR-200 and Cetrelimab for Patients with Muscle-Invasive Bladder Cancer Ineligible for or Refusing Platinum-Based Chemotherapy https://clinicaltrials.eu/trial/study-on-tar-200-and-cetrelimab-for-patients-with-muscle-invasive-bladder-cancer-ineligible-for-or-refusing-platinum-based-chemotherapy/ Wed, 29 Apr 2026 14:29:44 +0000 https://clinicaltrials.eu/trial/study-on-tar-200-and-cetrelimab-for-patients-with-muscle-invasive-bladder-cancer-ineligible-for-or-refusing-platinum-based-chemotherapy/ This clinical trial is focused on studying a type of bladder cancer known as Muscle-Invasive Urothelial Carcinoma. The study is exploring the effects of two treatments: a combination of TAR-200 and Cetrelimab, and Cetrelimab alone. TAR-200 is a device that helps deliver medication directly into the bladder, while Cetrelimab is a type of medication known as a monoclonal antibody, which is designed to help the immune system fight cancer cells.

The purpose of the study is to understand how these treatments can affect the tumor in patients who are scheduled for a surgery called radical cystectomy, which involves removing the bladder. The study is open-label, meaning both the researchers and participants know which treatment is being given. Participants in the study are those who cannot or choose not to receive a type of chemotherapy known as platinum-based chemotherapy before surgery.

Participants will be randomly assigned to one of two groups: one group will receive the combination of TAR-200 and Cetrelimab, and the other group will receive Cetrelimab alone. The study will monitor the effects of these treatments over a period of time to see how well they work in reducing the cancer before surgery. The study will also look at the safety of the treatments and any side effects that may occur. The goal is to gather information that could help improve treatment options for this type of bladder cancer in the future.

]]> Study of erdafitinib versus chemotherapy (gemcitabine or mitomycin) for patients with high-risk non-muscle-invasive bladder cancer with FGFR mutations who failed BCG therapy https://clinicaltrials.eu/trial/study-comparing-erdafitinib-and-chemotherapy-for-patients-with-high-risk-non-muscle-invasive-bladder-cancer-with-fgfr-mutations-or-fusions/ Wed, 29 Apr 2026 14:29:31 +0000 https://clinicaltrials.eu/trial/study-comparing-erdafitinib-and-chemotherapy-for-patients-with-high-risk-non-muscle-invasive-bladder-cancer-with-fgfr-mutations-or-fusions/ This study focuses on Non-Muscle-Invasive Bladder Cancer (NMIBC) that has specific genetic changes called FGFR mutations or fusions. The cancer being studied has returned after previous treatment with Bacillus Calmette-Guérin (BCG). The study compares two different treatments: an oral medication called erdafitinib (also known as JNJ-42756493) and standard chemotherapy medications (gemcitabine or mitomycin) that are placed directly into the bladder.

The main purpose of this research is to determine how well erdafitinib works compared to standard chemotherapy in preventing cancer from returning in patients with high-risk bladder cancer. The study will track how long patients remain free from cancer recurrence after starting treatment.

During the study, patients will be randomly assigned to receive either erdafitinib tablets taken by mouth, or chemotherapy treatment delivered directly into the bladder. The erdafitinib group will take the medication daily for up to 24 months. Patients receiving bladder chemotherapy will get treatment over a period of up to 7 days. The study will continue until early 2025.

]]> Study on TAR-200 and Cetrelimab for High-Risk Bladder Cancer Patients Not Responding to BCG and Unable or Unwilling to Have Surgery https://clinicaltrials.eu/trial/study-on-tar-200-and-cetrelimab-for-high-risk-bladder-cancer-patients-not-responding-to-bcg-and-unable-or-unwilling-to-have-surgery/ Wed, 29 Apr 2026 14:29:27 +0000 https://clinicaltrials.eu/trial/study-on-tar-200-and-cetrelimab-for-high-risk-bladder-cancer-patients-not-responding-to-bcg-and-unable-or-unwilling-to-have-surgery/ This clinical trial is focused on studying a type of bladder cancer known as Non-Muscle Invasive Bladder Cancer (NMIBC). This form of cancer affects the bladder but does not invade the muscle layer. The study is exploring the effectiveness and safety of different treatments for patients whose cancer has not responded to a common treatment called Intravesical Bacillus Calmette-Guérin (BCG) and who are not eligible for or have chosen not to undergo a major surgery called radical cystectomy. The treatments being tested include a drug-device combination called TAR-200, which is placed in the bladder, and a medication called Cetrelimab, which is given through an infusion into the vein. The study will look at these treatments both separately and in combination.

The purpose of the study is to evaluate how well these treatments work in eliminating cancer and preventing its return. Participants will be divided into different groups to receive either TAR-200 with Cetrelimab, TAR-200 alone, or Cetrelimab alone. The study will also include a group receiving TAR-200 alone for those with a specific type of papillary disease. Throughout the study, participants will undergo regular check-ups, including procedures like cystoscopies, which allow doctors to look inside the bladder, and biopsies, which involve taking small samples of tissue for examination. These procedures help in assessing the response to the treatment and monitoring any changes in the condition.

The study will last for several years, with participants receiving treatment over a period of time and being monitored for any signs of cancer recurrence or progression. The trial aims to provide valuable information on the potential benefits and safety of these treatments for patients with high-risk NMIBC. By participating, individuals contribute to research that may improve future treatment options for this type of bladder cancer.

]]> Study of RO7247669, Tiragolumab, and Atezolizumab for Patients with Untreated Advanced Urothelial Cancer Ineligible for Platinum Chemotherapy https://clinicaltrials.eu/trial/study-of-ro7247669-tiragolumab-and-atezolizumab-for-patients-with-untreated-advanced-urothelial-cancer-ineligible-for-platinum-chemotherapy/ Wed, 29 Apr 2026 14:28:56 +0000 https://clinicaltrials.eu/trial/study-of-ro7247669-tiragolumab-and-atezolizumab-for-patients-with-untreated-advanced-urothelial-cancer-ineligible-for-platinum-chemotherapy/ This clinical trial is focused on studying treatments for urothelial cancer, a type of cancer that affects the bladder and other parts of the urinary system. The study involves three different treatments: RO7247669, tiragolumab, and atezolizumab. RO7247669 is also known by the code name TOBEMSTOMIG. These treatments are types of immunotherapy, which help the body’s immune system fight cancer.

The purpose of the study is to evaluate how effective these treatments are in patients who have not received any previous treatment for their advanced or metastatic urothelial cancer and are not eligible for chemotherapy that contains platinum. The study will compare the effects of RO7247669 alone, RO7247669 combined with tiragolumab, and atezolizumab alone. Participants will receive these treatments through an intravenous infusion, which means the medication is given directly into a vein.

Throughout the study, participants will be monitored to see how their cancer responds to the treatment. The study will look at how many participants experience a reduction in their cancer, how long it takes for the cancer to progress, and overall survival rates. The study will also track any side effects that participants may experience. This research aims to find the most effective treatment option for patients with this type of cancer.

]]> Study of TAR-200 and Cetrelimab for Patients with Muscle-Invasive Bladder Cancer Not Undergoing Radical Cystectomy https://clinicaltrials.eu/trial/study-of-tar-200-and-cetrelimab-for-patients-with-muscle-invasive-bladder-cancer-not-undergoing-radical-cystectomy/ Wed, 29 Apr 2026 14:28:40 +0000 https://clinicaltrials.eu/trial/study-of-tar-200-and-cetrelimab-for-patients-with-muscle-invasive-bladder-cancer-not-undergoing-radical-cystectomy/ This clinical trial is focused on studying a type of bladder cancer known as Muscle-Invasive Bladder Cancer (MIBC). The study is evaluating a new treatment approach using a combination of two treatments: TAR-200 and Cetrelimab. TAR-200 is a device that delivers medication directly to the bladder, and Cetrelimab is a type of medication called a monoclonal antibody, which is designed to help the immune system fight cancer. The trial compares this combination to the standard treatment of chemoradiotherapy, which involves using chemotherapy and radiation therapy together.

The purpose of the study is to see if the combination of TAR-200 and Cetrelimab can help patients live longer without their cancer returning or spreading. Participants in the study will be randomly assigned to receive either the new combination treatment or the standard chemoradiotherapy. The study will last for several months, and participants will receive regular check-ups and monitoring to assess their health and the effectiveness of the treatment.

Throughout the study, participants will receive their treatments through intravenous infusions, which means the medication is given directly into a vein. The study aims to provide more information about the potential benefits and safety of using TAR-200 and Cetrelimab together for treating Muscle-Invasive Bladder Cancer. This research could lead to new treatment options for patients with this type of cancer.

]]> Study Comparing Erdafitinib and Mitomycin for Patients with Intermediate-risk Non-muscle Invasive Bladder Cancer with FGFR Gene Alterations https://clinicaltrials.eu/trial/study-comparing-erdafitinib-and-mitomycin-for-patients-with-intermediate-risk-non-muscle-invasive-bladder-cancer-with-fgfr-gene-alterations/ Wed, 29 Apr 2026 14:28:32 +0000 https://clinicaltrials.eu/trial/study-comparing-erdafitinib-and-mitomycin-for-patients-with-intermediate-risk-non-muscle-invasive-bladder-cancer-with-fgfr-gene-alterations/ This clinical trial is focused on studying a type of bladder cancer known as Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) that has specific changes in the FGFR gene. The study is comparing two treatments: a new system called TAR-210 that delivers the drug Erdafitinib directly into the bladder, and a single chemotherapy drug also given directly into the bladder. The chemotherapy drugs being studied are Mitomycin and Gemcitabine Hydrochloride. The purpose of the study is to see which treatment is more effective and safe for patients with this type of bladder cancer.

Participants in the study will be randomly assigned to receive either the TAR-210 system or one of the chemotherapy drugs. The study will last for up to 12 months, during which time the effects of the treatments will be monitored. The TAR-210 system uses a special device to place the medication directly into the bladder, which is a non-surgical procedure. The study aims to find out how long it takes for the cancer to return or worsen, or for any other serious health issues to occur.

This trial is important for understanding better treatment options for people with bladder cancer that has FGFR gene changes. By comparing these treatments, researchers hope to improve the management of this disease and provide more effective care for patients in the future.

]]> Study on Enfortumab Vedotin and Pembrolizumab for Patients with Advanced Urothelial Cancer https://clinicaltrials.eu/trial/study-on-enfortumab-vedotin-and-pembrolizumab-for-patients-with-advanced-urothelial-cancer/ Wed, 29 Apr 2026 14:26:44 +0000 https://clinicaltrials.eu/trial/study-on-enfortumab-vedotin-and-pembrolizumab-for-patients-with-advanced-urothelial-cancer/ This clinical trial is focused on studying the treatment of urothelial cancer, a type of cancer that occurs in the urinary system, including the bladder. The study is investigating the use of a medication called enfortumab vedotin, which is being tested both as a standalone treatment and in combination with other cancer therapies. One of the combinations being explored includes pembrolizumab, a medication that helps the immune system fight cancer. The purpose of the study is to assess the safety and effectiveness of these treatments in patients with urothelial cancer.

Participants in the study will receive the treatments through an intravenous infusion, which means the medication is delivered directly into the bloodstream through a vein. The study will monitor how well the treatments work in reducing the size of the cancer and how safe they are for patients. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatments.

The study will take place over a period of time, during which participants will have regular check-ups and assessments to track their progress. The goal is to gather information on how these treatments can help manage urothelial cancer and improve patient outcomes. This research is important for developing new and effective ways to treat this type of cancer.

]]> Study of Enfortumab Vedotin and Pembrolizumab for Patients with Advanced or Metastatic Urothelial Cancer https://clinicaltrials.eu/trial/study-of-enfortumab-vedotin-and-pembrolizumab-for-patients-with-advanced-or-metastatic-urothelial-cancer/ Wed, 29 Apr 2026 14:26:12 +0000 https://clinicaltrials.eu/trial/study-of-enfortumab-vedotin-and-pembrolizumab-for-patients-with-advanced-or-metastatic-urothelial-cancer/ This clinical trial is focused on studying treatments for urothelial cancer, a type of cancer that affects the bladder and other parts of the urinary system. The study is comparing two different treatment approaches. One group of participants will receive a combination of two medications: enfortumab vedotin and pembrolizumab. Pembrolizumab is also known by its code name, MK-3475. The other group will receive standard chemotherapy, which may include medications like gemcitabine, cisplatin, or carboplatin. These treatments are given as solutions through an infusion, which means they are delivered directly into the bloodstream through a vein.

The purpose of the study is to compare the effectiveness of the combination treatment with the standard chemotherapy in people who have not received prior treatment for their advanced or metastatic urothelial cancer. Participants will be randomly assigned to one of the two treatment groups. The study will monitor the participants over a period of time to see how well the cancer responds to the treatments and to assess overall survival rates.

Throughout the study, participants will receive regular medical check-ups and monitoring to ensure their safety and to track the progress of their treatment. The study aims to provide valuable information on whether the combination of enfortumab vedotin and pembrolizumab offers better outcomes compared to the standard chemotherapy options for patients with this type of cancer.

]]> Study comparing enfortumab vedotin versus chemotherapy combination (docetaxel, paclitaxel, vinflunine) in patients with previously treated advanced or metastatic bladder cancer https://clinicaltrials.eu/trial/study-comparing-enfortumab-vedotin-with-chemotherapy-for-patients-with-advanced-or-metastatic-bladder-cancer/ Wed, 29 Apr 2026 14:22:42 +0000 https://clinicaltrials.eu/trial/study-comparing-enfortumab-vedotin-with-chemotherapy-for-patients-with-advanced-or-metastatic-bladder-cancer/ This study focuses on patients with locally advanced or metastatic urothelial cancer, which is a type of cancer that develops in the urinary system. The research compares two treatment approaches: a medication called enfortumab vedotin versus standard chemotherapy drugs including vinflunine, docetaxel, or paclitaxel. All medications are given through intravenous administration (into a vein).

The main purpose of this research is to determine if enfortumab vedotin helps patients live longer compared to traditional chemotherapy treatments. The study is designed for patients whose cancer has continued to grow or spread after receiving previous treatments, including both platinum-based chemotherapy and immunotherapy.

During the study, patients will be randomly assigned to receive either enfortumab vedotin or one of the standard chemotherapy medications. The treatment will continue as long as it is helping the patient and side effects remain manageable. Throughout the study, doctors will monitor patients’ overall health, perform regular medical examinations, and evaluate how well the treatment is working.

]]> Study of Mitomycin-C with Electromotive Drug Administration before Surgery in Patients with Non-Muscle Invasive Bladder Cancer https://clinicaltrials.eu/trial/study-on-preoperative-mitomycin-c-treatment-for-patients-with-non-muscle-invasive-bladder-cancer/ Wed, 29 Apr 2026 14:22:40 +0000 https://clinicaltrials.eu/trial/study-on-preoperative-mitomycin-c-treatment-for-patients-with-non-muscle-invasive-bladder-cancer/ This clinical trial focuses on non-muscle invasive bladder cancer, a type of cancer that affects the inner lining of the bladder without spreading to the muscle layer. The study examines a treatment approach using mitomycin C, a medication that helps prevent cancer cells from growing and spreading. The medication will be administered in two different ways: through a special technique called electromotive drug administration (EMDA) before surgery, or through standard delivery after surgery.

The purpose of this research is to determine if giving mitomycin C using the EMDA method before a surgical procedure called transurethral resection (a surgery to remove abnormal tissue from the bladder) works better than the traditional method of giving the medication after surgery. The study will compare how long patients remain free from cancer return between these two different approaches.

During the study, patients will be randomly assigned to receive either the new EMDA treatment before surgery or the standard treatment after surgery. The medication will be delivered directly into the bladder through a thin tube. Patients will be monitored over time to check if their cancer returns or gets worse. The study will also look at how well patients tolerate the treatment and any side effects that may occur.

]]> Study of Pembrolizumab and Sacituzumab Govitecan for Patients with Muscle-Invasive Bladder Cancer Unable or Unwilling to Use Cisplatin-Based Chemotherapy https://clinicaltrials.eu/trial/study-of-pembrolizumab-and-sacituzumab-govitecan-for-patients-with-muscle-invasive-bladder-cancer-unable-or-unwilling-to-use-cisplatin-based-chemotherapy/ Wed, 29 Apr 2026 14:22:38 +0000 https://clinicaltrials.eu/trial/study-of-pembrolizumab-and-sacituzumab-govitecan-for-patients-with-muscle-invasive-bladder-cancer-unable-or-unwilling-to-use-cisplatin-based-chemotherapy/ This clinical trial is focused on studying a type of cancer called muscle-invasive bladder cancer. This is a condition where cancer cells have spread into the muscle wall of the bladder. The study is exploring the effects of two medications, pembrolizumab and sacituzumab govitecan, on patients who cannot receive or choose not to receive a common chemotherapy treatment known as cisplatin-based chemotherapy. Pembrolizumab, also known by its code name MK-3475, is a medication that helps the immune system fight cancer cells. Sacituzumab govitecan, also referred to as IMMU-132, is a type of treatment that combines an antibody with a drug to target and kill cancer cells.

The purpose of this study is to see if the combination of pembrolizumab and sacituzumab govitecan can lead to a complete response, meaning no signs of cancer are found in the tissue after surgery. Participants in the study will receive these medications through an intravenous infusion, which means the medicine is given directly into a vein. The study will follow a specific schedule where patients will receive the treatment over a period of time, and their health will be monitored closely to observe any changes or side effects. The study aims to understand how well these medications work together and how safe they are for patients.

Throughout the study, researchers will look at how many patients have a complete response to the treatment, as well as monitor any side effects that occur. They will also track how long patients live without the cancer getting worse, known as progression-free survival, and overall survival, which is the length of time patients live after starting the treatment. This information will help determine the effectiveness and safety of using pembrolizumab and sacituzumab govitecan for treating muscle-invasive bladder cancer.

]]> Study Comparing Sacituzumab Govitecan with Other Treatments for Patients with Advanced Unresectable Urothelial Cancer https://clinicaltrials.eu/trial/study-comparing-sacituzumab-govitecan-with-other-treatments-for-patients-with-advanced-unresectable-urothelial-cancer/ Wed, 29 Apr 2026 14:22:33 +0000 https://clinicaltrials.eu/trial/study-comparing-sacituzumab-govitecan-with-other-treatments-for-patients-with-advanced-unresectable-urothelial-cancer/ This clinical trial is focused on studying a type of cancer known as urothelial cancer, which affects the urinary system and can be either locally advanced or metastatic, meaning it has spread to other parts of the body. The study is comparing the effectiveness of a medication called sacituzumab govitecan with other treatments chosen by doctors. Sacituzumab govitecan is a type of medication known as an antibody-drug conjugate, which is designed to target and kill cancer cells.

The purpose of the study is to see how well sacituzumab govitecan works in helping patients live longer compared to other treatments. Participants in the study will receive either sacituzumab govitecan or a treatment selected by their doctor, which could include medications like docetaxel, vinflunine, or paclitaxel. These treatments are given as solutions for infusion, meaning they are administered directly into the bloodstream through a vein.

The study will follow participants over a period of time to monitor their health and the effects of the treatments. The goal is to gather information on how these treatments impact overall survival and other health outcomes in patients with advanced urothelial cancer. This information will help doctors understand which treatments may be most effective for this type of cancer.

]]>